Trials / Completed
CompletedNCT00621699
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- University Medicine Greifswald · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to confirm a significant influence of ezetimibe and tacrolimus on each others pharmacokinetics
Detailed description
Hypercholesterolemia is a frequent finding in organ transplant recipients receiving immunosuppressive drugs such as tacrolimus. To prevent increased cardiovascular morbidity and mortality in these patients, co-medication with lipid-lowering statins is recommended. However, treatment with statins is limited in many patients by insufficient cholesterol-lowering efficacy, drug interactions and serious adverse drug reactions (e.g. rhabdomyolysis). These patients may benefit from comedication with the cholesterol absorption inhibitor ezetimibe. Since tacrolimus and ezetimibe were shown to be substrates of the efflux transporter ABCB1 (P-glycoprotein), drug interactions between both compounds may occur. Therefore, this clinical study in healthy subjects was initiated to evaluate the clinical relevance of drug/drug interactions between tacrolimus and ezetimibe according to the accepted bioequivalence approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany | administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling |
| DRUG | 1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany | administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling |
| DRUG | 1 tablet Ezetrol(R) + 1 capsules Prograf(R) | administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2008-02-22
- Last updated
- 2008-02-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00621699. Inclusion in this directory is not an endorsement.